Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002682 | 0.74 | CYP19A1 (0.39) | GAAMAPTSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL8285022 | 0.72 | CHRNB2 (0.39) | TDP1ALDH1A1KMT2ACYP1A2KDM4E | |
| SCHEMBL28270390 | 0.71 | HRH1 (0.44) | GAAMAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL8283753 | 0.71 | CYP2C9 (0.35) | SMN1; SMN2ALDH1A1CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL10818102 | 0.71 | — | — | |
| SCHEMBL10815150 | 0.71 | CYP3A4 (0.35) | CYP3A4 | |
| SCHEMBL8283151 | 0.70 | GAA (0.50) | GAASMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL14074890 | 0.69 | ALDH1A1 (0.39) | GAAMAPTTDP1ALDH1A1KMT2A | |
| SCHEMBL14074892 | 0.69 | HSD11B1 (0.44) | MAPTALDH1A1KMT2AKDM4ECYP3A4 | |
| SCHEMBL4327266 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| EP-1664092-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009058856-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | GAA 128/4885MAPT 4108/4885SMN1; SMN2 3962/4885 |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | GAA 382/4885MAPT 4004/4885SMN1; SMN2 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.